UROtainer for Bladder Catheter Maintenance, Infection Prevention and Quality of Life
UROBIQ
Study of Uro-Tainer® Polihexanide and Uro-Tainer® With Citric Acid on Catheter Blockage, Infection Prevention, Cost-effectiveness and Quality of Life (UROBIQ): a Prospective Randomized Single-blinded Clinical Study
1 other identifier
interventional
70
1 country
1
Brief Summary
The purpose of the current study is to investigate whether catheter flushing with Uro-Tainer® with citric acid and Uro-Tainer® Polihexanide can: Reduce catheter changes due to incrustation and blockage. In addition, a list of secondary aims inclusive of cost-effectiveness analysis in collaboration with the Centre for Innovative Medical Technology (CIMT) at OUH.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started May 2022
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2022
CompletedFirst Submitted
Initial submission to the registry
December 17, 2022
CompletedFirst Posted
Study publicly available on registry
March 20, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2028
September 18, 2025
September 1, 2025
4.7 years
December 17, 2022
September 14, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of catheter changes during the treatment and follow-up period.
Number of catheter changes
1 year
Secondary Outcomes (8)
UTI events (Urinary tract infection event)
1 year
Urine culture
1 year
Odour
1 year
Quality of life by SF-36
1 year
Quality of life by ICIQ-LTCqol
1 year
- +3 more secondary outcomes
Study Arms (2)
Uro-Tainer® catheter flushing
EXPERIMENTALUro-Tainer® catheter flushing two times weekly for 3 months.
Saline catheter flushing
PLACEBO COMPARATORSaline solution catheter flushing two times weekly for 3 months.
Interventions
Clinical effect of preventive treatment - catheter flushing with UroTainer®
Clinical effect of preventive treatment - catheter flushing with saline solution
Eligibility Criteria
You may qualify if:
- Citizen not previously flushed
- A permanent catheter (suprapubic and urethral)
- Male and female \> 18 years of age
- Acute or previous catheter stop because of blocking or incrustations.
- The pilot project does not include clogging due to incrustations
- Voluntary consent to participate in the study, following a full explanation of the nature and purpose of the study, by signing the informed consent form approved by the Ethics Committee (EC) before all evaluations.
- Citizen previously flushed with NaCl or UroTainer®
- A permanent catheter (suprapubic and urethral)
- Male and female \> 18 years of age
- Willingness to take a rinse break for a minimum of 4 weeks. In the event of 2 catheter stops during the flushing break, assessed on the basis of an urgent need for catheter flushing with NaCl or catheter change, the citizen can be included.
- The pilot project does not include clogging due to incrustations
- If there is no catheter stop during the rinsing break, the citizen will continue without rinsing until a possible catheter stop.
- Voluntary consent to participate in the study, following a full explanation of the nature and purpose of the study, by signing the informed consent form approved by the Ethics Committee (EC) before all evaluations.
You may not qualify if:
- Urothelial cancer
- Bladder and kidney stones requiring treatment
- Age \< 18 years of age
- Pregnant and / or breastfeeding women
- Not able to understand Danish
- Dementia, where relatives can / will not give consent
- Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Odense University Hospital
Odense, 5000, Denmark
Study Officials
- PRINCIPAL INVESTIGATOR
Karin Andersen
University of Southern Denmark
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
December 17, 2022
First Posted
March 20, 2023
Study Start
May 1, 2022
Primary Completion (Estimated)
January 1, 2027
Study Completion (Estimated)
January 1, 2028
Last Updated
September 18, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share